ema | pharmaphorum

Skip to main content

Thursday 21 May 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

ema

News

European Medicines Agency London

Don't let Brexit disrupt European Medicines Agency, warn pha...

Heads of R&D at all major pharma companies have come together to express their concerns about severe disruption to the European Medicines Agency (EMA) as it faces a Brexit-induced reloc

News

European Medicines Agency London

UK hasn’t given up on keeping European Medicines Agency

The UK’s chief Brexit negotiator, minister David Davis will fight to keep the European Medicines Agency in London, despite the country leaving the EU.

News

brexit-5

Life sciences watches closely as Brexit negotiations loom

PM finally sets date for Brexit.

Views & Analysis

Patient power in europe more work to be done 570x320

Patient power in Europe – more work to be done

What the EMA and pharma can do to promote patient involvement in decision making.

News

brexit-5

Brexit could delay drug launches, former MHRA chief warns

Britain will be in "second or third tier" of drug launches, experts warn.

News

European Medicines Agency London

Could UK's post-Brexit regulator evaluate value as well?

But longer-term benefits could include faster reimbursement decisions.

Load more results

Editor's Picks

BMS signs $15.2bn R&D alliance with China's Hengrui

UK Health Secretary resigns, sparking leadership speculation

Reports: Makary out, Diamantas in as FDA commissioner

EU agrees plan to tackle essential medicine shortages

Clock starts ticking on UK's single patient record plan

News

Lilly's 'triple G' retatrutide aces crucial obesity trial

Lilly's 'triple G' retatrutide aces crucial obesity trial

Lilly's retatrutide achieved weight loss of more than 30% at two years in a new trial, firming up its credentials as a next-generation obesity drug.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company